Literature DB >> 23054444

Functional selectivity of adenosine A1 receptor ligands?

Ellen V Langemeijer1, Dennis Verzijl, Stefan J Dekker, Ad P Ijzerman.   

Abstract

The concept of functional selectivity offers great potential for the development of drugs that selectively activate a specific intracellular signaling pathway. During the last few years, it has become possible to systematically analyse compound libraries on G protein-coupled receptors (GPCRs) for this 'biased' form of signaling. We screened over 800 compounds targeting the class of adenosine A(1) receptors using a β-arrestin-mediated signaling assay in U2OS cells as a G protein-independent readout for GPCR activation. A selection of compounds was further analysed in a G protein-mediated GTPγS assay. Additionally, receptor affinity of these compounds was determined in a radioligand binding assay with the agonist [(3)H]CCPA. Of all compounds tested, only LUF5589 9 might be considered as functionally selective for the G protein-dependent pathway, particularly in view of a likely overestimation of β-arrestin signaling in the U2OS cells. Altogether, our study shows that functionally selective ligands for the adenosine A(1) receptor are rare, if existing at all. A thorough analysis of biased signaling on other GPCRs also reveals that only very few compounds can be considered functionally selective. This might indicate that the concept of functional selectivity is less common than speculated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054444      PMCID: PMC3568431          DOI: 10.1007/s11302-012-9334-3

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  38 in total

1.  Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers.

Authors:  Anikó Göblyös; Sabrina Neves Santiago; Daniele Pietra; Thea Mulder-Krieger; Jacobien von Frijtag Drabbe Künzel; Johannes Brussee; Adriaan P Ijzerman
Journal:  Bioorg Med Chem       Date:  2005-03-15       Impact factor: 3.641

2.  Internalization and desensitization of adenosine receptors.

Authors:  Elisabeth C Klaasse; Adriaan P Ijzerman; Willem J de Grip; Margot W Beukers
Journal:  Purinergic Signal       Date:  2007-11-13       Impact factor: 3.765

3.  Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.

Authors:  Y C Kim; M de Zwart; L Chang; S Moro; J K von Frijtag Drabbe Künzel; N Melman; A P IJzerman; K A Jacobson
Journal:  J Med Chem       Date:  1998-07-16       Impact factor: 7.446

Review 4.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

5.  Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Pharmacol Res       Date:  2008-03-08       Impact factor: 7.658

6.  A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.

Authors:  Jacobus P D van Veldhoven; Lisa C W Chang; Jacobien K von Frijtag Drabbe Künzel; Thea Mulder-Krieger; Regina Struensee-Link; Margot W Beukers; Johannes Brussee; Adriaan P IJzerman
Journal:  Bioorg Med Chem       Date:  2008-01-12       Impact factor: 3.641

Review 7.  Therapeutic potential of β-arrestin- and G protein-biased agonists.

Authors:  Erin J Whalen; Sudarshan Rajagopal; Robert J Lefkowitz
Journal:  Trends Mol Med       Date:  2010-12-21       Impact factor: 11.951

Review 8.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors.

Authors:  Eric Reiter; Seungkirl Ahn; Arun K Shukla; Robert J Lefkowitz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-09-19       Impact factor: 13.820

9.  Functional selectivity of adenosine receptor ligands.

Authors:  Dennis Verzijl; Ad P Ijzerman
Journal:  Purinergic Signal       Date:  2011-05-05       Impact factor: 3.765

10.  Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000.

Authors:  Zhan-Guo Gao; Kai Ye; Anikó Göblyös; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  BMC Pharmacol       Date:  2008-12-12
View more
  11 in total

Review 1.  Efficacy and ligand bias at the μ-opioid receptor.

Authors:  E Kelly
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

2.  Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist.

Authors:  Celine Valant; Lauren T May; Luigi Aurelio; Chung Hui Chuo; Paul J White; Jo-Anne Baltos; Patrick M Sexton; Peter J Scammells; Arthur Christopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-11       Impact factor: 11.205

Review 3.  New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism.

Authors:  Elizabeth A Vecchio; Jo-Anne Baltos; Anh T N Nguyen; Arthur Christopoulos; Paul J White; Lauren T May
Journal:  Br J Pharmacol       Date:  2018-06-21       Impact factor: 8.739

4.  Tissue-nonspecific alkaline phosphatase acts redundantly with PAP and NT5E to generate adenosine in the dorsal spinal cord.

Authors:  Sarah E Street; Nicholas J Kramer; Paul L Walsh; Bonnie Taylor-Blake; Manisha C Yadav; Ian F King; Pirkko Vihko; R Mark Wightman; José Luis Millán; Mark J Zylka
Journal:  J Neurosci       Date:  2013-07-03       Impact factor: 6.167

5.  Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor.

Authors:  Jo-Anne Baltos; Silvia Paoletta; Anh T N Nguyen; Karen J Gregory; Dilip K Tosh; Arthur Christopoulos; Kenneth A Jacobson; Lauren T May
Journal:  Mol Pharmacol       Date:  2016-05-02       Impact factor: 4.436

Review 6.  Molecular Simulations and Drug Discovery of Adenosine Receptors.

Authors:  Jinan Wang; Apurba Bhattarai; Hung N Do; Sana Akhter; Yinglong Miao
Journal:  Molecules       Date:  2022-03-22       Impact factor: 4.411

Review 7.  Exploring Adenosine Receptor Ligands: Potential Role in the Treatment of Cardiovascular Diseases.

Authors:  Werner J Geldenhuys; Ahmad Hanif; June Yun; Mohammed A Nayeem
Journal:  Molecules       Date:  2017-06-01       Impact factor: 4.411

8.  Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1.

Authors:  Anna Vlachodimou; Adriaan P IJzerman; Laura H Heitman
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

9.  Novel positive allosteric modulators of A2B adenosine receptor acting as bone mineralisation promoters.

Authors:  Elisabetta Barresi; Chiara Giacomelli; Laura Marchetti; Emma Baglini; Silvia Salerno; Giovanni Greco; Federico Da Settimo; Claudia Martini; Maria Letizia Trincavelli; Sabrina Taliani
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 10.  Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization.

Authors:  Stephen J Hill; Lauren T May; Barrie Kellam; Jeanette Woolard
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.